By: Giulia Corradetti, MD, Martin David Harp
At this year’s ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.
Giulia Corradetti, MD, a clinical instructor at UCLA and scientist at the Doheny Eye Institute, presented results from the Truckee trial at Harvard this year at the ARVO meeting in Denver, Colorado. Under the direction of Dr. Khanani, the study evaluated the association between baseline OCT biomarkers and treatment response in faricimab-treated neovascular AMD eyes.